FGFR1
protein-codingfibroblast growth factor receptor 1, the group of I-set domain containing|CD molecules|Receptor tyrosine kinases
Gene summary
The protein encoded by this gene is a member of the fibroblast growth factor receptor (FGFR) family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds both acidic and basic fibroblast growth factors and is involved in limb induction. Mutations in this gene have been associated with Pfeiffer syndrome, Jackson-Weiss syndrome, Antley-Bixler syndrome, osteoglophonic dysplasia, and autosomal dominant Kallmann syndrome 2. Chromosomal aberrations involving this gene are associated with stem cell myeloproliferative disorder and stem cell leukemia lymphoma syndrome. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized. [provided by RefSeq, Jul 2008]
- FLT2
- KAL2
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~68.6 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0008150
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0007043
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0007844
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0008150
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0007400
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0018800
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0008150
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0007043
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0014196
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0007844
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0007844
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0019659
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0007043
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0008150
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0014196
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0008150
Submitter: ClinGen
FGFR1 has been described in relation to autosomal dominant Osteoglophonic Dysplasia (OD) as early as 2005 by White et al. (PMID: 15625620). Clinical phenotypes of OD include brachy-turricephaly, midface hypoplasia, short stature, short/broad hands and feet, and failure to thrive due to feeding and respiratory difficulties in some cases. The mechanism of disease is dominant-positive gain of function variants, causing increased signalling of the FGFR1 protein (PMID: 15625620). At least 5 unique missense variants have been reported in the literature. Evidence supporting this gene-disease relationship includes case-level data, of 8 probands from 5 publications (PMIDs: 15625620, 31319224, 29147600, 20236123, 16470795). In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Craniofacial Malformations Gene Curation Expert Panel on 2/25/2021. Gene Clinical Validity Standard Operating Procedures (SOP) – Version 8.
Inheritance Pattern: AD
Disease ID:MONDO:0005486
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0018065
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0018555
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0019659
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0008150
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0013074
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0014196
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0013074
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0014196
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0014196
Submitter: ClinGen
*FGFR1* has been described in relation to autosomal dominant Hartsfield Syndrome (HS) as early as 2013 by Simonis et al. (PMID: 23812909). HS is characterized by the co-occurrence of holoprosencephaly, ectrodactyly, and cleft lip and palate. At least 19 unique missense variants have been reported in the literature. Evidence supporting this gene-disease relationship includes case-level data, of 20 probands from 11 publications (PMIDs: 23812909, 26931467, 27170295, 27363716, 27790375, 28825856, 30787447, 31512363, 32373773, 35338003, 38013637). Variants have been found throughout the catalytic domain of FGFR1 in patients with HS (between residues 458 and 765). The mechanism of pathogenicity appears to be dominant-negative (PMID: 21479780). For experimental data, the FaceBase database showed high expression in the maxillary and mandibullary regions (https://www.facebase.org/chaise/record/#1/isa:dataset/RID=1-X5HG). A mouse model was evaluated for this gene-disease relationship but was not counted towards the final score as it does not recapitulate the disease specific phenotypes (Calvert et al. 2011; PMID: 21479780). This gene-disease pair was originally evaluated by the Craniofacial Malformations GCEP on 2/18/2021 (SOP Version 8). It was reevaluated on 7/9/2026 (SOP Version 12). As a result of this reevaluation, new genetic evidence (PMIDs: 35338003, 38013637) and experimental data (FaceBase Expression) was scored, but the classification remained at moderate. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.
Inheritance Pattern: AD
Disease ID:MONDO:0019659
Submitter: ClinGen
FGFR1 has been repeatedly described in association with autosomal dominant Pfeiffer Syndrome Type I (PS1), a mild form of Pfeiffer Syndrome characterized by craniofacial anomalies, broad thumbs and big toes, and prematurely closed cranial sutures in some cases (Muenke et al. 1994; PMID: 7874169). One missense variant in FGFR1 is associated with PS1, and has been reported in at least 16 probands from 8 publications (PMIDs: 10861678, 14564217, 7874169, 16957473, 25251565, 24127277, 23348274, 24776567). This gene-disease association is also supported by experimental evidence including animal models, and an in vitro functional assay (PMIDs: 21538817, 10942429, 14613973). In summary, FGFR1 is definitively associated with autosomal dominant Pfeiffer Syndrome Type I. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Craniofacial Malformations Gene Curation Expert Panel on 5/20/2021. Gene Clinical Validity Standard Operating Procedures (SOP) – Version 8.
Inheritance Pattern: AD
Disease ID:MONDO:0014196
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0014196
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0008428
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0008150
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0007844
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Audiologic/Otolaryngologic; Craniofacial; Dental; Endocrine; Genitourinary; Musculoskeletal; Neurologic
Intervention: Audiologic/Otolaryngologic; Endocrine
Rationale: In Hypogonadotropic hypogonadism, surveillance in adolescence related to sexual maturation is indicated, as is monitoring of bone mineral density in order to allow early detection and treatment of disease; In order to induce and maintain secondary sex characteristics, gradually increasing doses of gonadal steroids (females: estrogen/progestin; males: testosterone/hCG) can be beneficial; Related to fertility, endocrinologic therapy (females: recombinant hCG or pulsatile GnRH therapy; males: hCG/HMG/recombinant FSH or pulsatile GnRH therapy) may be effective, though IVF may be required; Some individuals with FGFR1 variants may have hearing loss, and appropriate interventions may be beneficial as relates to language and speech development
Comments: Complex inheritance models, such as inolving digenic inheritance/synergistic effects (eg, with GNRHR, NELF, as well as other FGF8-network associated genes) has been reported
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to FGFR1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_023110.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 19 | 186 | 4 | 210 | |
| missense | 34 | 86 | 455 | 41 | 2 | 618 |
| nonsense | 19 | 14 | 5 | 38 | ||
| start loss | 0 | |||||
| frameshift | 53 | 21 | 9 | 83 | ||
| splice donor/acceptor (+/-2bp) | 16 | 25 | 6 | 47 | ||
| Total | 122 | 147 | 494 | 227 | 6 | 996 |
Highest pathogenic variant AF is 0.00002600734
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_075598.2 | 17 | MANE Select | |
| Ensembl | ENSP00000400162.2 | 17 | MANE Select | |
| RefSeq | NP_001167534.1 | 17 | Standard | |
| RefSeq | NP_001167535.1 | 17 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| fgfr1a | Danio rerio | Structure: olfactory bulb glomerulus Quality: malformed abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- PI3K-Akt signaling pathway - Homo sapiens (human)
- Central carbon metabolism in cancer - Homo sapiens (human)
- Adherens junction - Homo sapiens (human)
- Melanoma - Homo sapiens (human)
- Breast cancer - Homo sapiens (human)
Biological Process
- negative regulation of transcription by RNA polymerase II
- MAPK cascade
- skeletal system development
- ureteric bud development
- in utero embryonic development
Molecular Function
- protein tyrosine kinase activity
- transmembrane receptor protein tyrosine kinase activity
- fibroblast growth factor-activated receptor activity
- Ras guanyl-nucleotide exchange factor activity
- protein binding
Cellular Component
- extracellular region
- nucleolus
- cytosol
- plasma membrane
- integral component of plasma membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000425967
- Coding exons
- 18
- Length
- 57697
- Individuals with no LoFs
- 125709
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 28
- Defined
- 125737
- p
- 0.000111
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.49 | 348 | 505 | 0.689 | 0.0000318 | 5554 |
| Missense (PolyPhen) | 93 | 224.29 | 0.41464 | 2468 | ||
| Synonymous | -1.40 | 237 | 211 | 1.12 | 0.0000140 | 1699 |
| Loss of Function | 5.48 | 4 | 42.5 | 0.0940 | 0.00000234 | 490 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0.00010 | 0.000099 | rare |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0.000047 | 0.000046 | rare |
| European (Non-Finnish) | 0.000055 | 0.000053 | rare |
| South Asian | 0.00056 | 0.00056 | rare |
| Other | 0.00017 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation. {ECO:0000250|UniProtKB:P16092, ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11353842, ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1379697, ECO:0000269|PubMed:1379698, ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19261810, ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753, ECO:0000269|PubMed:20139426, ECO:0000269|PubMed:21765395, ECO:0000269|PubMed:8622701, ECO:0000269|PubMed:8663044}.;
- Disease
- DISEASE: Pfeiffer syndrome (PS) [MIM:101600]: A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3). {ECO:0000269|PubMed:7874169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hypogonadotropic hypogonadism 2 with or without anosmia (HH2) [MIM:147950]: A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic- pituitary axis. In some cases, it is associated with non- reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). {ECO:0000269|PubMed:12627230, ECO:0000269|PubMed:15001591, ECO:0000269|PubMed:15605412, ECO:0000269|PubMed:15845591, ECO:0000269|PubMed:16606836, ECO:0000269|PubMed:16757108, ECO:0000269|PubMed:16764984, ECO:0000269|PubMed:16882753, ECO:0000269|PubMed:17154279, ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:21700882, ECO:0000269|PubMed:22927827, ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900, ECO:0000269|PubMed:26277103}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry. Some patients carrying mutations in FGFR1 also have a mutation other HH-associated genes including DUSP6, FGF8, FGF17, FLRT3, GNRH1, GNRHR, HS6ST1, IL17RD, ANOS1, KISS1R, NSMF, PROKR2, SPRY4 and TACR3 (PubMed:23643382). {ECO:0000269|PubMed:23643382}.; DISEASE: Osteoglophonic dysplasia (OGD) [MIM:166250]: Characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant. {ECO:0000269|PubMed:15625620, ECO:0000269|PubMed:16470795}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hartsfield syndrome (HRTFDS) [MIM:615465]: A syndrome characterized by the triad of holoprosencephaly, ectrodactyly, and cleft/lip palate. Profound mental retardation is also present. Multiple other congenital anomalies usually occur. {ECO:0000269|PubMed:23812909, ECO:0000269|PubMed:24888332}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Trigonocephaly 1 (TRIGNO1) [MIM:190440]: A keel-shaped deformation of the forehead, caused by premature fusion of the metopic sutures. It results in a triangular shape of the head. {ECO:0000269|PubMed:11173846}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow. {ECO:0000269|PubMed:9716603}.; DISEASE: Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity. {ECO:0000269|PubMed:10688839, ECO:0000269|PubMed:15034873, ECO:0000269|PubMed:16946300, ECO:0000269|PubMed:17389761, ECO:0000269|PubMed:9949182}.; DISEASE: Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CNTRL. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CNTRL-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity.; DISEASE: Encephalocraniocutaneous lipomatosis (ECCL) [MIM:613001]: A sporadically occurring, neurocutaneous disorder characterized by ocular anomalies, skin lesions, and central nervous system anomalies. Clinical features include a well-demarcated hairless fatty nevus on the scalp, benign ocular tumors, intracranial and intraspinal lipomas, and congenital abnormalities of the meninges. Seizures, spasticity, and intellectual disability can be present. {ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:26942290}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence. {ECO:0000269|PubMed:10861678}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.786
Intolerance Scores
- LoFtool
- 0.00524
- RVIS EVS
- -1.35
- RVIS percentile EVS
- 4.58
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- H
- Indispensability pred.
- E
- Indispensability score
- 0.933
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |